The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy - Report - MDSpire

The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy

  • By

  • Shaobo Qin

  • Zhicheng Dai

  • Zhenxing Hu

  • Xiaohui Wang

  • Huiyan Zhang

  • Haotian Yang

  • Jie Liu

  • Lianghong Ma

  • July 8, 2026

  • 0 min

Share

Clinical Report: Mapping the Expression Patterns and Variability of Nectin-4, HER2, and Trop-2 in Urothelial Carcinoma

Overview

This study investigates the expression patterns of Nectin-4, HER2, and Trop-2 in urothelial carcinoma (UC). High expression of at least one target was found in 90.7% of patients, with significant co-expression and variability noted across different tumor stages.

Background

Urothelial carcinoma is a prevalent malignancy with significant biological heterogeneity. Antibody-drug conjugates (ADCs) have emerged as a therapeutic option, yet their efficacy varies based on target expression and tumor characteristics.

Data Highlights

FindingValue
High expression of at least one target90.7%
Multi-target co-expression56.8%
HER2 upregulation (CIS to invasive carcinoma)P = 0.034
Trop-2 upregulation (CIS to invasive carcinoma)P = 0.039
Trop-2 expression (lower vs upper urinary tract)P = 0.042

Key Findings

  • 90.7% of patients exhibited high expression of at least one target (Nectin-4, HER2, Trop-2).
  • 56.8% of patients showed multi-target co-expression.
  • HER2 and Trop-2 were significantly upregulated from carcinoma in situ to invasive carcinoma (P = 0.034 and P = 0.039, respectively).
  • Nectin-4 expression tended to downregulate in metastases.
  • A high Δ-Trop-2 score was independently associated with muscle invasion, lymphovascular invasion, and metastasis.

Clinical Implications

The findings indicate the need for further research into the expression patterns of therapeutic targets in urothelial carcinoma.

Conclusion

This study highlights the expression patterns of therapeutic targets in urothelial carcinoma.

Related Resources & Content

  1. FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma - PMC
  2. World Journal of Urology — TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinoma
  3. The ASCO Post — How Do Novel Genetic Subtypes of Urothelial Carcinoma Respond to Immune Checkpoint Blockade?
  4. The Impact of N-cadherin Expression on Prognosis in Upper Tract Urothelial Carcinoma Patients: Findings from a Multi-Center Study
  5. Elevated TROP-2 Levels in Papillary Renal Cell Carcinoma Indicate Its Promise as a Target for Antibody-Drug-Conjugate Treatment
  6. FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer | FDA
  7. FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma - PMC
  8. FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer | FDA

Original Source(s)

The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy

  • by Shaobo Qin, Zhicheng Dai, Zhenxing Hu, Xiaohui Wang, Huiyan Zhang, Haotian Yang, Jie Liu, Lianghong Ma

  • July 8, 2026

Related Content

The role of 18F-FDG PET/CT in identifying risk factors for ground-glass nodules in invasive lung adenocarcinoma

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial

CAR-T cell signaling dynamics, rational design principles and artificial intelligence for next-generation chimeric antigen receptors